Muscle injuries in dogs occur in active, athletic animals as well as in domestic pets. Injuries most often occur during intense exercise, sudden twists, jumps, or collisions. Untreated injuries can lead to scarring, chronic pain, and loss of mobility.
Traditional treatment includes rest, cold compresses, anti-inflammatory drugs, and gradual rehabilitation. Although these methods bring relief, they often do not ensure complete muscle tissue regeneration.
PRP contains growth factors that stimulate angiogenesis and muscle cell proliferation. When applied topically, it promotes rapid healing, reduces inflammation, and limits scarring.
MSCs accelerate muscle fiber regeneration, reduce inflammation, and promote the formation of healthy tissue instead of scar tissue. They can be used for more serious muscle damage or chronic injuries.
👉 Check out how mesenchymal stem cells work
In cases of severe inflammation or chronic pain following injury, blocking the IL-1 pathway can reduce inflammation and improve your dog's comfort..
👉 Learn more about IL-1 pain therapy and treatment
Stage 1 – fresh muscle injuries: PRP as the first line of biological healing support.
Stage 2 – more serious injuries or recurrent injuries: MSC to accelerate regeneration and reduce complications.
Stage 3 – chronic inflammation: IL-1 in combination with rehabilitation and pain management.
Muscle injuries in dogs can significantly limit the animal's fitness and activity. Standard treatment is often insufficient, which is why biological therapies – PRP and MSC – supported by IL-1 in cases of chronic inflammation are becoming increasingly important. They enable faster healing, reduce complications, and allow the dog to return to full activity.
PRP is used for fresh and moderate injuries. MSC is more effective for more serious injuries.
The first effects are visible after a few weeks, and full recovery may take 2–3 months.
Yes – they use the patient's own material (blood, adipose tissue), which minimizes the risk of complications.
No—they are mainly used in chronic inflammatory conditions when other therapies do not bring about sufficient improvement.
